Aprepitant


Generic Medicine Info
Administration
May be taken with or without food.
Contraindications
Co-admin w/ astemizole, cisapride, pimozide, terfenadine.
Special Precautions
Moderate to severe hepatic impairment. Pregnancy and lactation. Patient Counselling This drug may cause dizziness and fatigue, if affected, do not drive or operate machinery. Monitoring Parameters Monitor INR/protohrombin time (in patients taking warfarin) for 2 wk (particularly at 7-10 days) following admin; signs/symptoms of hypersensitivity reaction.
Adverse Reactions
Headache, constipation, diarrhoea, dyspepsia, anorexia, fatigue, hiccups, eructation, dizziness, increased ALT or AST levels, abdominal pain, oedema, tinnitus, neutropenic colitis, chills, gait disturbances, flushing, epigastric discomfort, dysgeusia, dry mouth, stomatitis, thirst, polyuria, dysuria, haematuria, urinary frequency, arthralgia, myalgia, muscular weakness, hyperglycaemia, disorientation, euphoria, anxiety, photosensitivity, skin disorders (e.g. rash, pruritus), anaemia, febrile neutropenia, HTN or hypotension, palpitations, bradycardia, hyponatraemia, hypokalaemia, insomnia, drowsiness, miosis, reduced visual acuity, wt changes, sensory disturbances, throat irritation, sneezing, abnormal bowel sounds, acid reflux, perforating duodenal ulcer, dyspnoea, cough, wheezing, hyperhidrosis, conjunctivitis, pharyngitis, resp tract infections, UTI, candidiasis, herpes simplex.
Potentially Fatal: Hypersensitivity reactions (e.g. Stevens-Johnson syndrome, anaphylaxis, angioedema).
Drug Interactions
May increase exposure of oral CYP3A4 substrates. May reduce plasma concentration of drugs metabolised by CYP2C9 isoenzyme (e.g. warfarin, phenytoin, tolbutamide). May increase exposure to corticosteroids. May reduce the efficacy of OCs. Reduced plasma levels w/ strong CYP3A4 inducers (e.g. rifampicin, carbamazepine, phenobarbital). Increased plasma levels w/ CYP3A4 inhibitors (e.g. ketoconazole, clarithromycin, nefazodone, protease inhibitors). May enhance serum levels of tolvaptan.
ATC Classification
A04AD12 - aprepitant ; Belongs to the class of other antiemetics.
Disclaimer: This information is independently developed by CIMS based on aprepitant from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in